Merck Announces Third-Quarter 2012 Financial Results

Merck continues to expect full-year 2012 revenues to be at or near 2011 levels on a constant currency basis. At current exchange rates, sales would be affected unfavorably by approximately 1 percent for the fourth quarter and more than 2 percent for the full year.

In addition, the company expects full-year 2012 non-GAAP R&D expenses to be higher than the 2011 level. The company continues to expect the full-year 2012 non-GAAP tax rate to be approximately 25 percent.

A reconciliation of anticipated 2012 EPS as reported in accordance with GAAP to non-GAAP EPS that excludes certain items is provided in the table below.

$ in millions, except EPS amounts		Full-Year 2012
GAAP EPS		$2.08 to $2.24
Difference 3		1.70 to 1.58
Non-GAAP EPS that excludes items listed below		$3.78 to $3.82
Acquisition-related costs 4		$5,300 to $5,100
Restructuring costs		1,100 to 800
Net decrease (increase) in income before taxes		6,400 to 5,900
Estimated income tax (benefit) expense		(1,160) to (1,050)
Decrease (increase) in net income		$5,240 to $4,850

Total Employees

As of Sept. 30, 2012, Merck had approximately 84,000 employees worldwide.

« First ‹ Previous ... 3 4 5 6 7 8 9 10 11 Next › Last »